Please wait while the formulary information is being retrieved.
ABACAVIR-LAMIVUDINE (ABACAVIR SULFATE/LAMIVUDINE)
- HIV infection
600 mg-300 mg tablet
- 1 tablet by oral route once daily
abacavir 600 mg-lamivudine 300 mg tablet
- 1 tablet by oral route once daily
HIV infection
- 1 tablet by oral route once daily
- None
Contraindicated
- None
Severe
Moderate
- None
- Acute pancreatitis
- Chronic pancreatitis
- Disease of liver
- HLa-B 57:01 positive
- Lactating mother
- Lactic acidosis
- Pancreatitis
- Severe hepatic disease
Contraindicated
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
Severe
Moderate
- Coronary artery disease
- Hypertriglyceridemia
- Kidney disease with likely reduction in GFR
ABACAVIR-LAMIVUDINE (ABACAVIR SULFATE/LAMIVUDINE)
- HIV infection
- Hypersensitivity drug reaction
- Depression
- Diarrhea
- Dizziness
- Fatigue
- Gastritis
- Headache disorder
- Insomnia
- Malaise
- Migraine
- Nausea
- Skin rash
- Symptoms of anxiety
- Vertigo
More Frequent
Severe
Less Severe
- Cough
- Pharyngitis
- Acute abdominal pain
- Dream disorder
- Fever
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Anaphylaxis
- Anemia
- Aplastic anemia
- Erythema multiforme
- Increased creatine kinase level
- Lactic acidosis
- Lymphadenopathy
- Pancreatitis
- Peripheral neuropathy
- Pure red cell aplasia
- Rhabdomyolysis
- Seizure disorder
- Splenomegaly
- Steatosis of liver
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
- Urticaria
Less Severe
- Alopecia
- Arthralgias
- Dyspnea
- Elevated serum amylase
- General weakness
- Hyperglycemia
- Muscle weakness
- Paresthesia
- Pruritus of skin
- Stomatitis
- Wheezing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Abacavir and Lamivudine
Use single ingredient products weight < 25 kg.
- 1 Day – 8 Years
- Use single ingredient products weight < 25 kg.
Abacavir
- Severity Level:
2
- Additional Notes: Art preg registry data show no increased risk for major birth defects
Lamivudine
- Severity Level:
2
- Additional Notes: No fda cat;art preg registry data show no increased risk for major birth defects
Contraindicated
Abacavir
Cdc does not recommend breastfeeding in hiv-positive women
Avoid breastfeeding in hiv positive women per cdc
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Lamivudine
Cdc does not recommend breastfeeding in hiv-positive women
Avoid breastfeeding in hiv positive women per cdc
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Avoid breastfeeding in hiv positive women per cdc |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- In some patients, the abacavir in this product has caused a serious (sometimes fatal) allergic reaction. Your doctor should order a blood test to measure your risk before you start this medication or take it again. If the blood test shows you are at greater risk, you should not take this medication and your doctor should discuss other treatment choices with you.<br /><br />Symptoms of an allergic reaction may include any of the following: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing, fever, extreme tiredness, nausea, vomiting, diarrhea, stomach pain, muscle aches, sore throat, mouth sores, or cough. Get medical help right away if you experience any of these symptoms. If you have stopped taking abacavir because of an allergic reaction, you must never take any form of abacavir again, or death could result.<br /><br />Tell all of your doctors and pharmacists if you have stopped taking abacavir due to an allergic reaction. Also, properly throw away any unused medications containing abacavir. Read the warning card provided with this medication for more details.<br /><br /> If you have hepatitis B infection and HIV, you may have a serious worsening of hepatitis symptoms if you stop taking lamivudine. Talk with your doctor before stopping this medication. Your doctor will monitor liver tests for several months after you stop lamivudine. Get medical help right away if you develop symptoms of worsening liver problems.
HIV infection | |
B20 | Human immunodeficiency virus [HIv] disease |
B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
0-9 | A-Z |
---|---|
B20 | Human immunodeficiency virus [HIv] disease |
B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool